Colibri Heart Valve, LLC Announces Continued Enrollment in the Company's Feasibility Study of the First Ready-to-Use Transcatheter Heart Valve System
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BROOMFIELD, CO, July 24, 2013 (GLOBE NEWSWIRE) -- Colibri Heart Valve, LLC, a privately held medical device company, today announced that enrollment in the Company's first-in-human feasibility study is continuing, and early clinical results from the second implantation of the Colibri device confirm the positive clinical findings observed in its first use. The Colibri transcatheter aortic valve implantation (TAVI) system (US Patent 8,361,144) is the world's first and only low profile, 14 French, pre-mounted, pre-crimped, and pre-packaged, ready-for-use TAVI system. Colibri plans to provide updates on the first-in-human feasibility study at the upcoming London Valve Summit and TCT conferences in September and October respectively.
Help employers find you! Check out all the jobs and post your resume.
BROOMFIELD, CO, July 24, 2013 (GLOBE NEWSWIRE) -- Colibri Heart Valve, LLC, a privately held medical device company, today announced that enrollment in the Company's first-in-human feasibility study is continuing, and early clinical results from the second implantation of the Colibri device confirm the positive clinical findings observed in its first use. The Colibri transcatheter aortic valve implantation (TAVI) system (US Patent 8,361,144) is the world's first and only low profile, 14 French, pre-mounted, pre-crimped, and pre-packaged, ready-for-use TAVI system. Colibri plans to provide updates on the first-in-human feasibility study at the upcoming London Valve Summit and TCT conferences in September and October respectively.
Help employers find you! Check out all the jobs and post your resume.